



## An assessment of willingness to participate in a randomized trial of arthroscopic knee surgery in patients with osteoarthritis<sup>☆</sup>

Alisha H. Creel<sup>a</sup>, Elena Losina<sup>a,c</sup>, Lisa A. Mandl<sup>e</sup>, Robert J. Marx<sup>e</sup>,  
Nizar N. Mahomed<sup>d</sup>, Scott D. Martin<sup>b</sup>, Tamara L. Martin<sup>b</sup>, Peter J. Millett<sup>b</sup>,  
Anne H. Fossel<sup>a</sup>, Jeffrey N. Katz<sup>a,b,\*</sup>

<sup>a</sup>Section of Clinical Sciences, Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, United States

<sup>b</sup>Department of Orthopedic Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States

<sup>c</sup>Department of Biostatistics, Boston University School of Public Health, Boston, MA, United States

<sup>d</sup>Toronto Western Hospital, Toronto, ON, Canada

<sup>e</sup>Hospital for Special Surgery, Weill Medical College of Cornell University, New York, NY, United States

Received 15 July 2004; accepted 22 December 2004

### Abstract

Identifying barriers to recruitment into a randomized clinical trial can help researchers adjust recruitment strategies to maximize enrollment. To determine barriers to enrollment of patients in trials of knee osteoarthritis treatments, we recruited from three centers patients over age 45 who had both knee osteoarthritis and a meniscal tear. We described a hypothetical randomized trial of arthroscopic partial meniscectomy versus non-operative management and assessed patients' willingness to participate in such a trial. We elicited preferences for treatment along with information on age, sex, education level, race, work status, and pain. We examined the association between these factors and willingness to participate in the trial. Orthopedic surgeons identified 106 eligible osteoarthritis patients, of whom 12 could not be reached, 6 refused and 88 (83%) completed interviews. 63% were female, 55% were college graduates, 23% were non-white and mean age was  $60 \pm 8$ . The mean WOMAC pain score was  $56 \pm 23$ . 22% of patients stated that they were definitely willing to participate in the hypothetical trial, and 24% stated they were probably willing. Subjects lacking strong preferences for treatment stated a greater willingness to

<sup>☆</sup> Funding: NIH P60 AR 47782, NIH K24 AR 02123, the Arthritis Foundation and the Research and Education Foundation of the American College of Rheumatology.

\* Corresponding author. Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115, United States. Tel.: +1 617 732 5356; fax: +1 617 732 5505.

E-mail address: [jnkatz@partners.org](mailto:jnkatz@partners.org) (J.N. Katz).

participate than those with strong preferences (36–14% definitely willing,  $\chi^2$  for trend,  $p=0.005$ ). WOMAC pain score, age, education, work status and race were not associated with willingness to participate. Males were more likely than females to state a willingness to participate (39–11% definitely willing,  $p=0.005$ ). Since OA affects females disproportionately, a better understanding of barriers to females' participation in trials may enhance future research on treatment of osteoarthritis. Effectively addressing a priori treatment preferences through patient education about the advantages and drawbacks of treatments may increase willingness to participate in trials.

© 2005 Elsevier Inc. All rights reserved.

*Keywords:* Randomized controlled trials; Recruitment; Preferences; Osteoarthritis; Arthroscopy

---

## 1. Introduction

Randomized controlled clinical trials are the most rigorous way to determine treatment efficacy. Recruitment into clinical trials, however, is notoriously difficult in general [1–5], and surgical trials in particular face further obstacles to recruitment [6–8]. Low recruitment leads to poor statistical power to detect meaningful differences, subjecting participants to potentially risky interventions with no guarantee that their participation will lead to results of scientific value [9]. From a practical standpoint, low recruitment may prompt a study sponsor to shut down the trial [1,2]. For all these reasons, investigators planning a randomized controlled clinical trial must ensure that recruitment of subjects into the trial will be sufficient to achieve the study aims.

In addressing issues of trial recruitment, investigators have tried to identify barriers to clinician and patient participation [1–3,10], to modify trials to make them more palatable to clinicians and patients [11–13], and to assess differences between those patients who agree to participate in trials and those who refuse [12,14–16]. Some have audiotaped clinician discussions with potential trial participants [11,17], while others have used surveys and focus groups to gather patients' general attitudes towards trial participation [3,5]. Other investigators have conducted surveys and interviews to elicit patient reactions to aspects of a specific trial, their feelings about the interventions proposed, and their potential willingness to participate in the hypothetical trial [10,12,15,16,18–20]. Demographic factors, such as gender, race, age and education level, have been associated in some studies with willingness to participate [1,2,5,14]. Patients' equipoise—that is, their belief that both treatments will be equally efficacious to them—has been shown to be important [10,19,20], as has the extent to which patients wish to control the course of treatment [16]. Finally, the specific treatment that a patient desires may influence willingness to participate in a trial and also compliance and satisfaction with trial participation for those who enroll [21–24].

Halpern has proposed a method called “prospective preference assessment” to improve recruitment for a planned trial, by helping forecast enrollment rates, simulate recruitment, identify problem areas and illuminate differences between participants and non-participants [12,25]. The method involves presenting a hypothetical trial design and using both quantitative and qualitative measures to elicit willingness to participate in the trial along with the motivations and concerns participants have about trial participation. Such interviews also include demographic and disease-specific data to investigate the ways in which people who express willingness to participate differ from those who do not.

We undertook a prospective preference assessment by performing a pilot study in planning for a trial of arthroscopic partial meniscectomy versus non-operative therapy in the setting of osteoarthritis and meniscal tear. Osteoarthritis (OA) is a prevalent and costly condition. One-third of people over age 65

have radiographic evidence of OA [26,27], and there is a 10% prevalence of symptomatic knee OA in the US [28]. Up to 80% of people with knee OA have meniscal tears on MRI [29]. Symptomatic meniscal tears may cause pain, clicking, popping, giving way and locking in the knee. Since pain, however, is also a cardinal symptom of OA, it can be difficult to determine the primary cause of symptoms in patients with OA and meniscal tears.

There are two main types of treatment for people who have both a meniscal tear and OA. One type is non-operative or conservative therapy, which includes the use of non-steroidal anti-inflammatory drugs (NSAIDs), injections of corticosteroids or hyaluronic acid, and exercises to strengthen the knee and increase flexibility.

The other type of therapy is arthroscopic partial meniscectomy (APM), a resection of the torn part of the meniscus to a stable edge. APM is the most common orthopedic procedure performed in the US [30], and over 80% of younger patients have alleviation of their pain post-procedure, with a complication rate of <2% [31,32]. There is some evidence, however, that APM may accelerate the progression of OA [33–35].

Furthermore, the effectiveness of APM in patients with OA is less clear, as rates of pain relief and functional improvement are lower than in patients without OA [31–33,36]. Therefore, the effectiveness of APM in the population of patients with both meniscal tears and OA is uncertain and optimal management of this population is unclear.

In an attempt to define optimal management in this clinical setting, we are planning a randomized trial of APM versus non-operative treatment in patients with both a meniscal tear and OA. Both arms of the trial are active, mirroring the clinical choices that are typically presented to patients with meniscal disorders and OA. In planning this trial, it was critical to understand what proportion of eligible patients in that population would be willing to participate in such a trial and to identify factors associated with patients' willingness to enroll.

Therefore, the aims of our pilot prospective preference assessment study were twofold: (1) to estimate the proportion of eligible patients who would be willing to enroll in a hypothetical trial; and (2) to identify factors associated with willingness to enroll in the trial. This would allow us to make effective changes in trial design and recruitment strategy prior to starting the RCT and to determine whether patients willing to participate in our trial are representative of the general osteoarthritis population.

We hypothesized that stated willingness to enroll in the hypothetical trial will decrease with increased strength of treatment preference.

## 2. Methods

### 2.1. Patient sample

We recruited patients in three centers who were age 45 or older, who had acute knee pain for at least 4 weeks with mechanical symptoms indicative of a meniscal tear, and who additionally had radiographic evidence of OA (Kellgren and Lawrence grades I, II, or III) and a strong clinical suspicion of a meniscal tear based on history, physical exam, and radiographic and imaging features. Patients were excluded if they had prior APM on the index knee, a locked knee, severe OA (Kellgren and Lawrence grade IV), or chondrocalcinosis. Participating surgeons identified eligible patients during regular office appointments. Surgeons explained the pilot study to the patients and referred them to the research assistant at each

center. The research assistant either met with the patient in person after the appointment to administer the interview or subsequently administered the interview by telephone; both interview methods used a standardized script. This study was approved by the institutional review boards of the three centers.

## 2.2. Patient interview

The script explained that the goal of the pilot investigation was to “help plan a research study.” The scripted interview presented the two treatment options: APM or “intensified physical therapy and medications.” After stating that each treatment succeeds in some patients and fails in others, the script described the proposed randomized trial as the best method for determining which treatment works best and under what circumstances. We then explained the process of randomization.

After the explanation of the hypothetical randomized clinical trial, patients rated their willingness to participate in such a trial on a five-point scale (definitely yes, probably yes, not sure, probably not, definitely not). Patients then explained (in open ended format) the reasons for their response. Patients were then asked if they had a preference between the treatments. If they did, we asked which treatment they preferred and whether they slightly or strongly preferred that treatment. They additionally answered a free response item explaining the reasons for their treatment preference. During the interview, the research assistant also administered the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) 5-item pain scale [37] and asked questions about race/ethnicity, education level and work status.

## 2.3. Statistical analysis

Willingness to participate was evaluated as a three-category variable: (1) definitely willing to participate, (2) probably willing to participate or unsure, and (3) probably or definitely not willing to participate (referred to simply as “not willing”). We dichotomized the treatment preference variable, either for surgery or physical therapy plus medications, into the categories “strong preference” versus all other responses, which were categorized as “no strong preference.”

We examined the association of age, sex, education, race, work situation and WOMAC pain score with both willingness to participate and strength of preference. Age was defined as a continuous variable. Education was categorized as high school or lower, some college or technical college, or college graduate or higher. Race was defined as white or non-white. Work situation was categorized as working either full- or part-time, not working due to knee or other health problems, and retired/otherwise not working. WOMAC pain scores were scaled from 0 to 100 with 100 representing no pain and 0 maximum pain. Chi-square and *t*-test were used to examine the association between categorical and continuous variables, respectively.

## 3. Results

Eleven orthopedic surgeons identified 119 patients at three centers. Of these, 13 (11%) were found ineligible either because they had undergone prior surgery on the index knee or because they were less than 45 years of age. Of the 106 eligible patients, six (6%) refused to participate and 12 (11%) could not be reached, leaving 88 (83%) patients who completed the interview.

Table 1  
Distribution of participants by willingness to participate

Factor	Definitely willing (n=19)	Probably willing or unsure (n=30)	Not willing (n=39)	Total (n=88)	p-value
Age (mean±SD)	58±8	59±9	62±8	60±8	0.25
<i>Sex</i>					
Male	13 (39)	7 (21)	13 (39)	33	0.005
Female	6 (11)	23 (42)	26 (47)	55	
<i>Education</i>					
High school or lower	5 (36)	5 (36)	4 (29)	14	0.57
Some college or technical college	4 (15)	10 (39)	12 (46)	26	
College graduate	10 (21)	15 (31)	23 (48)	48	
<i>Race</i>					
Nonwhite	4 (20)	9 (45)	7 (35)	20	0.49
White	15 (22)	21 (31)	32 (47)	68	
<i>Work status</i>					
Working	13 (25)	17 (33)	22 (42)	52	0.28
Not working due to knee/health	4 (36)	4 (36)	3 (27)	11	
Retired or otherwise not working	2 (8)	9 (36)	14 (56)	25	
WOMAC pain score (mean±SD)	56±24	56±18	56±26	56±23	

Table 2  
Distribution of participants by strength of treatment preference

Factor	Strong preference (n=57)	No strong preference (n=31)	p-value
Age (mean±SD)	61±8	59±8	0.43
<i>Sex</i>			
Male	18 (55)	15 (46)	0.12
Female	39 (71)	16 (29)	
<i>Education</i>			
High school or lower	9 (64)	5 (36)	0.64
Some college or technical college	15 (58)	11 (42)	
College graduate	33 (69)	15 (31)	
<i>Race</i>			
Nonwhite	12 (60)	8 (40)	0.61
White	45 (66)	23 (34)	
<i>Work status</i>			
Working	34 (65)	18 (35)	0.99
Not working due to knee/health	7 (64)	4 (36)	
Retired or otherwise not working	16 (64)	9 (36)	
WOMAC pain score (mean±SD)	59±23	50±22	




Fig. 1. Strength of preference and willingness to participate.

Of the 88 interviewed, 63% were female, 55% were college graduates, 23% were non-white, 59% were working full or part time, and the mean age was  $60 \pm 8$  years (range 45–81). The mean WOMAC pain score was  $56 \pm 23$ .

Nearly half of the participants expressed some degree of willingness to participate in the hypothetical trial, with 22% saying they were definitely willing, 24% probably willing, 10% unsure, and 21% and 24% probably and definitely not willing to participate, respectively. The majority of patients, 65%, had a strong preference for treatment of their knee problem.

Patients willing to participate did not differ from patients less likely to participate with respect to age, education, race, work status or WOMAC pain score (Table 1). Males, however, were more likely than females to state a willingness to participate, with 39% of males and 11% of females stating they were definitely willing ( $p=0.005$ ). Table 2 shows the distribution of strength of treatment preferences. Sex, age, education, race, work situation and WOMAC pain score did not show a significant association with strength of preference for one treatment or the other.

Willingness to participate and strength of preference were strongly related (Fig. 1), with 36% of patients that had no strong preferences for treatment being definitely willing to participate in a randomized trial compared to 14% of those with strong preferences ( $\chi^2$  for trend,  $p=0.005$ ).

#### 4. Discussion

We used the recently described technique of prospective preference assessment [25] to estimate participation in a planned randomized controlled trial of arthroscopic surgery versus non operative therapy in patients with symptomatic meniscal tears and concomitant osteoarthritis. Over one-fifth of participants stated a definite willingness to participate in a randomized trial, and another one-third stated probable willingness to participate or were unsure. Such hypothetical questioning about willingness to take part in a randomized trial has been shown to correlate with actual subsequent trial participation in an



AIDS vaccine trial with participants at high risk for the disease [12]. While the hypothetical assessment of willingness to participate is helpful in planning trials, it is important to understand that this measure is not precise. For example, in the vaccine trial, some participants who expressed hypothetical willingness to participate did not enroll, and a few who expressed unwillingness to participate eventually did enroll.

We found that males were more likely than females to state a willingness to participate in a hypothetical trial, reflecting findings from other similar studies [13,19]. It is unclear whether men are also more likely to participate in actual trials. It is plausible that women decline because they have greater caretaking responsibilities [2] or that they have greater mistrust of the medical establishment [38]. One study found that women appeared to have a better understanding of a hypothetical trial design than men and that they also expressed unwillingness to participate at higher rates than men [13]. These findings may relate to differing levels of risk aversion between women and men, though the literature on this issue is sparse and inconclusive [39]. OA is more prevalent in females than in males [40], and ensuring the inclusion of women in trials is crucial to the future impact of OA research. It is also worth noting that 63% of our survey participants were female, while most studies of meniscectomy have greater numbers of men than women [41]. Our cohort was older relative to many studies of meniscectomy, and female representation in such studies increases with increasing age of cohort. These findings, however, raise the question of whether there are different rates of operation between males and females presenting with meniscal tear and OA.

As expected, willingness to participate was strongly associated with strength of treatment preference (Fig. 1), with those having stronger preferences being less willing to participate in a randomized trial. This finding is consistent with prior literature [10,16,20] and has face validity. Patients who strongly prefer one treatment over another will more often find randomization troubling, as they could possibly get a less desired treatment. Clinical equipoise is the ethical requirement for doing trials [42], and a physician's equipoise has been linked to trial participation and successful recruitment by physicians [1,2,4,11,43]. A *patient's* equipoise, however, may be the key to the decision to enroll in a trial comparing two readily available treatment options: our data suggest that to be willing to participate, patients must believe that either treatment will be of equal benefit [10,19,20,44–47]. This may not be true of a trial offering a new treatment not otherwise available, where the chance of receiving a novel therapy is a possible inducement to enrollment.

In addition to the hypothetical nature of the question on willingness to participate, the survey is cross-sectional, and we do not know how willingness to participate and treatment preferences change over time. It is possible, for example, that someone with a strong treatment preference could learn more about the pitfalls of the preferred treatment or of advantages of the other, and thereby develop greater willingness to participate in a randomized trial. It is also possible that more knowledge could lead to a stronger preference for one treatment, leading to decreased willingness to participate. Some studies have shown that greater understanding about trial and treatment details leads to lower willingness to participate in trials, though little research has been done on this question [13,20]. We did not assess patient understanding of the trial design or of the treatments for their knee problem, so we cannot address this question.

The modest sample size and three-center design precluded examination of the effect of surgeons and centers on willingness to participate or on treatment preferences. Within the context of trial recruitment, physician presentation of a trial can have an effect on patients' willingness to participate [11,17] and can lead to different levels of recruitment from each physician [4]. Different centers may have an effect on recruitment, with possible factors including varying levels of staff experience and

motivation to aid in recruitment and varying patient experience with clinical research. These factors may affect patients' willingness to participate and merit further study. We also did not assess clinical factors such as body mass index and physical activity which are associated with OA. It is possible that such factors could be associated with willingness to participate in OA trials, creating concerns about generalizability of trial results.

The recruitment stage for randomized controlled trials should include eliciting patient preferences, to ensure that all potential participants accurately understand the efficacy of each treatment, to ensure generalizability, and to understand the effects of preferences on enrollment rates among potentially eligible patients and on trial outcomes for those who are randomized. As our data show, treatment preferences are strongly related to willingness to be randomized. Educating all potential participants, particularly those who have strong preferences based upon anecdotal evidence or false perceptions about the effectiveness of the treatments [48], may help them understand and perhaps even develop equipoise about the treatments. This, in turn, may increase patients' willingness to participate and maximize recruitment. For patients who agree to participate, knowing pre-existing preferences is essential, as those who do not get their preferred treatment may be less compliant with treatment, drop out or cross over more often, or have worse outcomes not based on the effect of treatment [24]. If preference for one treatment is greater in the study population, this effect will bias the results of treatment [22,23], especially if one treatment requires high levels of patient participation, such as physical therapy [21]. Education during the recruitment stage may increase the number enrolled who are without treatment preferences, which may increase compliance with treatment and reduce dropout from a trial.

In summary, the prospective preference approach efficiently assists investigators in assessing how many eligible patients may be willing to participate in a randomized trial. This method also provides some assessment of the differences between those who are willing and not willing to participate, and understanding such differences is a prerequisite to addressing them. Investigators can elicit the range of treatment preferences in those willing and unwilling to participate in randomized trials and include evidence-based information about treatment options to minimize impact of treatment preferences on willingness to participate.

## Acknowledgements

We would like to thank Christine Curcio and Diane Laing for their data collection and recruitment work; our surgeons for recruiting patients; and the clinical and administrative staff at all centers who supported our efforts.

## References

- [1] Ross S, Grant A, Counsell C, et al. Barriers to participation in randomised controlled trials: a systematic review. *J Clin Epidemiol* 1999;52:1143–56.
- [2] Lovato LC, Hill K, Hertert S, et al. Recruitment for controlled clinical trials: literature summary and annotated bibliography. *Control Clin Trials* 1997;18:328–52.
- [3] Cassileth BR, Lusk EJ, Miller DS, et al. Attitudes toward clinical trials among patients and the public. *JAMA* 1982;248:968–70.



- [4] Tognoni G, Alli C, Avanzini F, et al. Randomised clinical trials in general practice: lessons from a failure. *BMJ* 1991;303:969–71.
- [5] Donovan JL, Brindle L, Mills N. Capturing users' experiences of participating in cancer trials. *Eur J Cancer Care (Engl)* 2002;11:210–4.
- [6] Love JW. Drugs and operations. Some important differences. *JAMA* 1975;232:37–8.
- [7] McLeod RS, Wright JG, Solomon MJ, et al. Randomized controlled trials in surgery: issues and problems. *Surgery* 1996;119:483–6.
- [8] Birkmeyer NJ, Weinstein JN, Tosteson AN, et al. Design of the Spine Patient outcomes Research Trial (SPORT). *Spine* 2002;27:1361–72.
- [9] Halpern SD, Karlawish JH, Berlin JA. The continuing unethical conduct of underpowered clinical trials. *JAMA* 2002;288:358–62.
- [10] Mills N, Donovan JL, Smith M, et al. Perceptions of equipoise are crucial to trial participation: a qualitative study of men in the ProtecT study. *Control Clin Trials* 2003;24:272–82.
- [11] Donovan J, Mills N, Smith M, et al. Quality improvement report: improving design and conduct of randomised trials by embedding them in qualitative research: ProtecT (prostate testing for cancer and treatment) study. Commentary: presenting unbiased information to patients can be difficult. *BMJ* 2002;325:766–70.
- [12] Halpern SD, Metzger DS, Berlin JA, et al. Who will enroll? Predicting participation in a phase II AIDS vaccine trial. *J Acquir Immune Defic Syndr* 2001;27:281–8.
- [13] Llewellyn-Thomas HA, Thiel EC, Sem FW, et al. Presenting clinical trial information: a comparison of methods. *Patient Educ Couns* 1995;25:97–107.
- [14] Grant III CH, Cissna KN, Rosenfeld LB. Patients' perceptions of physicians communication and outcomes of the accrual to trial process. *Health Commun* 2000;12:23–39.
- [15] Halpern SD, Karlawish JH, Casarett D, et al. Hypertensive patients' willingness to participate in placebo-controlled trials: implications for recruitment efficiency. *Am Heart J* 2003;146:985–92.
- [16] Llewellyn-Thomas HA, McGreal MJ, Thiel EC, et al. Patients' willingness to enter clinical trials: measuring the association with perceived benefit and preference for decision participation. *Soc Sci Med* 1991;32:35–42.
- [17] Roberts F. Qualitative differences among cancer clinical trial explanations. *Soc Sci Med* 2002;55:1947–55.
- [18] Donovan J, Hamdy F, Neal D, et al. Prostate testing for cancer and treatment (ProtecT) feasibility study. *Health Technol Assess* 2003;7:1–88.
- [19] Ubel PA, Merz JF, Shea J, et al. How preliminary data affect people's stated willingness to enter a hypothetical randomized controlled trial. *J Investig Med* 1997;45:561–6.
- [20] Wragg JA, Robinson EJ, Lilford RJ. Information presentation and decisions to enter clinical trials: a hypothetical trial of hormone replacement therapy. *Soc Sci Med* 2000;51:453–62.
- [21] Brewin CR, Bradley C. Patient preferences and randomised clinical trials. *BMJ* 1989;299:313–5.
- [22] Halpern SD. Evaluating preference effects in partially unblinded, randomized clinical trials. *J Clin Epidemiol* 2003;56:109–15.
- [23] McPherson K, Britton AR, Wennberg JE. Are randomized controlled trials controlled? Patient preferences and unblind trials. *J R Soc Med* 1997;90:652–6.
- [24] Silverman WA, Altman DG. Patients' preferences and randomised trials. *Lancet* 1996;347:171–4.
- [25] Halpern SD. Prospective preference assessment: a method to enhance the ethics and efficiency of randomized controlled trials. *Control Clin Trials* 2002;23:274–88.
- [26] Jordan JM, Linder GF, Renner JB, et al. The impact of arthritis in rural populations. *Arthritis Care Res* 1995;8:242–50.
- [27] Felson DT, Zhang Y. An update on the epidemiology of knee and hip osteoarthritis with a view to prevention. *Arthritis Rheum* 1998;41:1343–55.
- [28] Felson DT, Anderson JJ, Naimark A, et al. Obesity and knee osteoarthritis. The Framingham Study. *Ann Intern Med* 1988;109:18–24.
- [29] Bhattacharyya T, Gale D, Dewire P, et al. The clinical importance of meniscal tears demonstrated by magnetic resonance imaging in osteoarthritis of the knee. *J Bone Jt Surg, Am* 2003;85-A:4–9.
- [30] Number of ambulatory surgery procedures by procedure category in the US: 1996. National Center for Health Statistics, 1998, p. 7.
- [31] Matsusue Y, Thomson NL. Arthroscopic partial medial meniscectomy in patients over 40 years old: a 5- to 11-year follow-up study. *Arthroscopy* 1996;12:39–44.

- [32] Katz JN, Harris TM, Larson MG, et al. Predictors of functional outcomes after arthroscopic partial meniscectomy. *J Rheumatol* 1992;19:1938–42.
- [33] Schimmer RC, Brulhart KB, Duff C, et al. Arthroscopic partial meniscectomy: a 12-year follow-up and two-step evaluation of the long-term course. *Arthroscopy* 1998;14:136–42.
- [34] Covall DJ, Wasilewski SA. Roentgenographic changes after arthroscopic meniscectomy: five-year follow-up in patients more than 45 years old. *Arthroscopy* 1992;8:242–6.
- [35] Cicuttini FM, Forbes A, Yuanyuan W, et al. Rate of knee cartilage loss after partial meniscectomy. *J Rheumatol* 2002;29:1954–6.
- [36] Englund M, Roos EM, Roos HP, et al. Patient-relevant outcomes fourteen years after meniscectomy: influence of type of meniscal tear and size of resection. *Rheumatology (Oxford)* 2001;40:631–9.
- [37] Bellamy N, Buchanan WW, Goldsmith CH, et al. Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. *J Rheumatol* 1988;15:1833–40.
- [38] Karlson EW, Daltroy LH, Liang MH, et al. Gender differences in patient preferences may underlie differential utilization of elective surgery. *Am J Med* 1997;102:524–30.
- [39] Rosen AB, Tsai JS, Downs SM. Variations in risk attitude across race, gender, and education. *Med Decis Mak* 2003;23:511–7.
- [40] Davis MA, Ettinger WH, Neuhaus JM, et al. Sex differences in osteoarthritis of the knee. The role of obesity. *Am J Epidemiol* 1988;127:1019–30.
- [41] Meredith DS, Losina E, Mahomed NN, et al. Determinants of functional and radiographic outcomes after arthroscopic partial meniscectomy. *Arthroscopy*; in press.
- [42] Freedman B. Equipoise and the ethics of clinical research. *N Engl J Med* 1987;317:141–5.
- [43] Taylor KM, Margolese RG, Soskolne CL. Physicians' reasons for not entering eligible patients in a randomized clinical trial of surgery for breast cancer. *N Engl J Med* 1984;310:1363–7.
- [44] Angell M. Patients' preferences in randomized clinical trials. *N Engl J Med* 1984;310:1385–7.
- [45] Chard JA, Lilford RJ. The use of equipoise in clinical trials. *Soc Sci Med* 1998;47:891–8.
- [46] Karlawish JH, Lantos J. Community equipoise and the architecture of clinical research. *Camb Q Healthc Ethics* 1997;6:385–96.
- [47] McQuellon RP, Muss HB, Hoffman SL, et al. Patient preferences for treatment of metastatic breast cancer: a study of women with early-stage breast cancer. *J Clin Oncol* 1995;13:858–68.
- [48] Redelmeier DA, Rozin P, Kahneman D. Understanding patients' decisions. Cognitive and emotional perspectives. *JAMA* 1993;270:72–6.